Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic LeukemiaJan A. Burger, Thomas J. Kipps, Osnat Bairey et al.|New England Journal of Medicine|2015Cited by 1.6k
Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter studyJorge J. Castillo, Steven P. Treon, Gilad Itchaki et al.|Blood|2018Cited by 100
Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Constantine S. Tam, Andrew W. Roberts, Stephen Opat et al.|Blood|2016Cited by 37